phase I clinical study
Hummingbird Bioscience, Novogene Partner to ID Cancer Patients With NRG1 Fusions in China
Novogene will use next-generation sequencing to identify solid tumor patients eligible to enroll in clinical trials of Hummingbird's anti-HER3 agent, HMBD-001.
MapKure, Personalis Partner to Screen Patients for BRAF Inhibitor Trial
Personalis plans to develop a companion diagnostic to MapKure's BRAF inhibitor, BGB-3245, once biomarkers have been identified in the study.
Kronos Bio Doses First Patient in CDK9 Inhibitor Trial With Tempus Performing Sequencing
Kronos is working with Tempus to sequence patients' tumor samples in the study for MYC amplification and overexpression.
Merus, Sema4 Partner to Accelerate Enrollment in Zenocutuzumab Trial
Sema4 will use its next-generation sequencing testing services to identify patients with solid tumors harboring NRG1 fusions for Merus' Phase I/II drug trial.
Novellus, Tempus Partner to Enroll Patients in BRAF Inhibitor Clinical Trial Program
The Jerusalem-based drug developer is studying PLX8394 in patients with BRAF V600-mutated gliomas and solid tumors with non-V600 mutations.Â
May 16, 2019
Jan 12, 2012
Jun 9, 2011
Mar 25, 2010